Octarine (Octarine Bio IVS) is a synthetic biology company that aims to develop psilocybin and cannabinoid derivatives.


Octarine has raised a total of U$3 million in funding over four rounds. Their latest funding was raised on March 11th, 2021 from a Seed round.

“Using our unique biosynthetic platform we engineer microorganisms to produce a range of natural and novel cannabinoid and psilocybin derived molecules with improved pharmacokinetic and therapeutic properties.”


At the start of 2020, the company announced that they received (seed) funding from Oskare Capital and Bruce Linton (former CEO of Canopy Growth Cooperation). Previously they were part of the BioInnovation Institute’s Business Acceleration Academy program (BAA-program).

Key Staff

  • Nethaji Gallage, CEO & Co-founder
  • Nick Milne, CSO & Co-founder
  • Maria Jesus
  • Victor Forman


Nick Milne previously worked as a postdoc at DTU Biosustain (The Novo Nordisk Foundation Center for Biosustainability) and Octarine was spun out from here.


Company Information

Octarine Website

January, 2019


B2C Biotech Drug Discovery

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships

Company News

Strengthening the European Psychedelic Ecosystem: Partnership Between Octarine Bio and Clerkenwell Health (Volteface, 01 June 2021)
Volteface (an independent research and advocacy organisation) reports on the cooperation between Clerkenwell Health and Octarine Bio.


HQ / Office Fruebjergvej 3, 2100 København, Denmark